{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:38:50Z","timestamp":1787841530515,"version":"build-2784847793"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We previously reported the 21-gene Oncotype DX\u00ae assay results from TransNEOS in patients enrolled in the phase 3 NEOS trial. However, the association between assay results and long-term prognosis has remained unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Of the 296 patients registered in TransNEOS, 226 patients were enrolled in this study. Multigene assay results were categorized into three groups based on Recurrence Score\u00ae (RS): RS low\u2009&lt;\u200911, RS intermediate 11\u201325, RS high\u2009&gt;\u200925. Kaplan\u2013Meier methods evaluated the association between RS results and DDFS and OS across treatments and clinical response to neoadjuvant endocrine treatment (NET).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The clinical efficacy of NET was judged as CR, PR, and SD in 4 (1.8%), 113 (50%), and 109 (48.2%) patients, respectively. In the RS low and intermediate groups, no statistically significant difference in DDFS or OS was observed between the endocrine therapy (ET) alone group and the chemoendocrine therapy (CT\u2009+\u2009ET) group. In the RS high group, OS was significantly lower in the ET group compared to the CT\u2009+\u2009ET group (p\u2009=\u20090.037). Among patients in the RS high group who achieved CR\u2009+\u2009PR response to NET, there was no significant difference in OS between the CT\u2009+\u2009ET group and the ET alone group (p\u2009=\u20090.25). However, the number of events was limited, and the study may have been underpowered to detect a meaningful difference.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The need for chemotherapy in postmenopausal HR\u2009+\u2009, HER2- breast cancer patients might be further informed by integrating the results of the Oncotype DX test with the response to NET.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12282-026-01862-3","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:51:31Z","timestamp":1781743891000},"page":"1004-1013","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognosis of ER-positive, HER2-negative postmenopausal early breast cancer patients based on response to neoadjuvant endocrine therapy and multigene assay results: findings from the NEOS trial"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0242-4718","authenticated-orcid":false,"given":"Hiroji","family":"Iwata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norikazu","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Toyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kashiwaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichiro","family":"Ohtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naruto","family":"Taira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiko","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshie","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikiya","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuhiro","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Sakamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy A.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"1862_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jema A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1862_CR2","first-page":"477","volume":"74","author":"A Giaquinto","year":"2024","unstructured":"Giaquinto A, Sung H, Newman LA, Freedman RA, Smith RA, Star J, et al. Breast cancer statistics 2024. CA Cancer J Clin. 2024;74:477\u201395.","journal-title":"CA Cancer J Clin"},{"key":"1862_CR3","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","volume":"390","author":"D Slamon","year":"2024","unstructured":"Slamon D, Lipatov O, Nowecki Z, McAndrew N, Kukielka-Budny B, Stroyakovskiy D, et al. Ribociclib plus endocrine therapy in early breast cancer. N Engl J Med. 2024;390:1080\u201391.","journal-title":"N Engl J Med"},{"issue":"1","key":"1862_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","volume":"24","author":"SRD Johnston","year":"2023","unstructured":"Johnston SRD, Toi M, O\u2019Shaughnessy J, Rastogi P, Campone M, Neven P, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24(1):77\u201390.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1862_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S1470-2045(20)30534-9","volume":"22","author":"M Toi","year":"2021","unstructured":"Toi M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, et al. Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(1):74\u201384.","journal-title":"Lancet Oncol"},{"key":"1862_CR6","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Breast Cancer. Version4.2025. https:\/\/www.nccn.org\/professionals\/physician_gls"},{"issue":"9938","key":"1862_CR7","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164\u201372.","journal-title":"Lancet"},{"issue":"15","key":"1862_CR8","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","volume":"30","author":"G Von Minckwitz","year":"2012","unstructured":"Von Minckwitz G, Untch M, Blohmer J-U, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796\u2013804.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1862_CR9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/jnci\/djk020","volume":"99","author":"M Dowsett","year":"2007","unstructured":"Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A\u2019Hern R, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2007;99(2):167\u201370.","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"1862_CR10","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","volume":"24","author":"S Paik","year":"2006","unstructured":"Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726\u201334.","journal-title":"J Clin Oncol"},{"issue":"25","key":"1862_CR11","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","volume":"385","author":"K Kalinsky","year":"2021","unstructured":"Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385(25):2336\u201347.","journal-title":"N Engl J Med"},{"issue":"2","key":"1862_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","volume":"379","author":"JA Sparano","year":"2018","unstructured":"Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant chemotherapy guided by a 21-Gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111\u201321.","journal-title":"N Engl J Med"},{"issue":"2","key":"1862_CR13","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10549-023-06874-7","volume":"199","author":"H Iwata","year":"2023","unstructured":"Iwata H, Yamamoto Y, Sakai T, Hasegawa Y, Nakamura R, Akabane H, et al. Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with\/without adjuvant chemotherapy. Breast Cancer Res Treat. 2023;199(2):231\u201341.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1862_CR14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10549-018-4964-y","volume":"173","author":"H Iwata","year":"2019","unstructured":"Iwata H, Masuda N, Yamamoto Y, Fujisawa T, Toyama T, Kashiwaba M, et al. Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study. Breast Cancer Res Treat. 2019;173(1):123\u201333.","journal-title":"Breast Cancer Res Treat"},{"key":"1862_CR15","unstructured":"General Rules for Clinical and Pathological Recording of Breast cancer. 15th edition. 2005"},{"key":"1862_CR16","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1200\/GO.20.00575","volume":"7","author":"K AlSaleh","year":"2021","unstructured":"AlSaleh K, Zahwahry H-AI, Bounedjar A, Oukkal M, Saadeddine A, Mahfouf H, et al. Response to induction neoadjuvant hormonal therapy using upfront 21-gene breast recurrence score assay\u2014results from the SAFIA phase III trial. JCO Global Oncol. 2021;7:811\u20139.","journal-title":"JCO Global Oncol"},{"issue":"1","key":"1862_CR17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1470-2045(09)70314-6","volume":"11","author":"KS Albain","year":"2010","unstructured":"Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55\u201365.","journal-title":"Lancet Oncol"},{"key":"1862_CR18","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1200\/JCO.21.02759","volume":"40","author":"U Nitz","year":"2022","unstructured":"Nitz U, Gluz O, Kumal S, Christgen M, Braun M, Aktas B, et al. Endocrine therapy response and 21-gene expression assay for therapy guidance in HR+\/HER2\u2013 early breast cancer. J Clin Oncol. 2022;40:2557\u201367.","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01862-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01862-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01862-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:59:04Z","timestamp":1787839144000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-026-01862-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1862"],"URL":"https:\/\/doi.org\/10.1007\/s12282-026-01862-3","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Hiroji Iwata serves as a consultant to AstraZeneca, Chugai, Daiichi Sankyo, Eli Lilly, MSD, Pfizer, Gilead Sciences, and CMIC, received research grants from Chugai, AstraZeneca, MSD, Daiichi Sanklyo, and Novartis, and received honoraria for lectures from Chugai, AstraZeneca, Eli Lilly, MSD, Pfizer, Gilead Sciences, and Myriad Genetics. Norikazu Masuda received research grants from Chugai, Eli Lilly, AstraZeneca, Pfizer, MSD, Daiichi Sanklyo, Eisai, Gilead Sciences, Novartis, and Oni-Pharma, received honoraria for lectures from Chugai, AstraZeneca, Eli Lilly, Daiichi Sankyo, Pfizer, Gilead Sciences, and Eisai, and served on the board of directors, unpaid, 2021\u20132025 at JCOG, board of directors, unpaid, 2007-current at JBCRG, board of directors, unpaid, 2021\u20132024 at Japanese Breast Cancer Society (JBCS), board of directors, unpaid, 2023\u20132025 at Japan Society of Clinical Oncology (JSCO), board of directors, unpaid, 2024-current at Japan Association of Breast Cancer Screening (JABCS), and board of directors, unpaid, 2025-current at KBCRN. Yutaka Yamamoto received research grants from Chugai, AstraZeneca, MSD, Daiichi Sanklyo, Novartis, Gilead Sciences, and Ono-Pharma, received honoraria for lectures from Chugai, AstraZeneca, Eli Lilly, Daiichi Sankyo, Pfizer, Gilead Sciences, Eisai, Kyowa-Kirin, Taiho, Takeda, Sysmex, Exact Science, Novartis, and MSD, received honoraria as advisory member from AstraZeneca, Pfizer, MSD, and Daiichi Sankyo, and served on the board of directors, unpaid, at JBCS and JBCRG. Tomomi\u00a0Fujisawa has no conflict of interest. Tatsuya Toyama received honoraria for lectures from Chugai, Eli Lilly, Daiichi Sankyo, Pfizer, Taiho, MSD, and Novartis. Masahiro Kashiwaba has no conflict of interest. Shoichiro Ohtani received honoraria for lectures from Eli Lilly and Eisai. Naruto Taira received research grants from Eisai, Chugai, Daiichi Sanklyo, Kyowa Kirin, Taiho, and Eli Lilly, received honoraria for lectures from Chugai, Eli Lilly, Daiichi Sankyo, Pfizer, Takeda, MSD, Boehringer Ingelheim, Eisai, Kyowa-Kirin, and AstraZeneca, and served on the board of directors, unpaid, at JBCS. Takehiko Sakai has no conflict of interest. Yoshie Hasegawa has no conflict of interest. Rikiya Nakamura received honoraria for lectures from AstraZeneca, Kyowa-Kirin, and Eli Lilly. Takuhiro Yamaguchi serves as a consultant to Public Health Research Foundation, EPS Corporation, Japan Tobacco Inc, Ono-Pharma, Kowa Company, Ltd, Chugai, Daiichi-Sankyo, Eisai, Sonire, MSD, Boehringer Ingelheim, and Kakeshi Inc, received research grants from Kyowa-Kirin, Tsumura & Co, Daiichi Sankyo, Otsuka Pharma, Solasia Pharma, Cordis, and NTT DOCOMO, Inc, and received honoraria as advisory member from Incyte Biosciences Japan. Kentaro Sakamaki serves as a consultant to Ono-Pharma. Christy A Russell is an Employee of Exact Sciences. Naoko\u00a0Sugiyama is an Employee of Exact Sciences.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}